Q-omics provides the consensus-scored P2RY2 profile across patient tissues and cancer cell-line models. P2RY2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, P2RY2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, P2RY2 RNA expression shows 15,831 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where P2RY2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P2RY2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P2RY2 survival associations across molecular data types. P2RY2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P2RY2 RNA expression–survival associations across cancer types. High P2RY2 expression shows unfavorable associations in MESO, KIRC, LGG, PAAD, UVM and GBM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for P2RY2 RNA expression.
This table summarizes P2RY2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for P2RY2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P2RY2 shows lower tumor expression in KIRC, KIRP, COAD and KICH and higher tumor expression in BLCA and UCEC. The KIRC box plot shows higher P2RY2 RNA expression in normal versus tumor tissue (log2 FC = −0.934, t-test p < 0.001).
This table shows molecular features associated with P2RY2 in patient tissues and cancer cell lines. In patient samples, P2RY2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, P2RY2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
